Therefore, the IL-6/COX-II-miR-137 axis may represent a novel pathogenesis of RA-FLS autoimmune inflammation and hsa-miR-137 can be a novel therapeutic target for the treatment of RA exacerbation. Here, IL6 is linked to rheumatoid arthritis.